About: Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 13 January 2017

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2017 (ast) наукова стаття, опублікована в січні 2017 (uk) مقالة علمية نشرت في 13 يناير 2017 (ar) scientific article published on 13 January 2017 (en) գիտական հոդված հրատարակված 2017 թվականի հունվարի 13-ին (hy)
publication date	wds:Q37587722-B82FFB05-273B-4DE2-8C67-5A169FE835EC
publication date	2017-01-13 00:00:00Z (xsd:dateTime)
cites work	wds:Q37587722-24F2F8DD-58EC-4B24-A893-1C367E05E9E3 wds:Q37587722-2653B7AF-BDA7-4B42-A2DB-44EC5B9A70AB wds:Q37587722-2882580D-8276-41FB-AC4B-FD765243C497 wds:Q37587722-2D26323A-3D3F-482C-B7DB-375B90C67D0F wds:Q37587722-3B41C4AF-DA55-4CCA-833A-8A2D01843724 wds:Q37587722-3C14464C-946C-4FEA-BA0B-58BA3414F66E wds:Q37587722-4EBD619F-480A-4D74-84DB-A7F5D8D7F295 wds:Q37587722-5309D423-062D-40E4-A2A1-F416293C9C62 wds:Q37587722-6C19C0D4-1B9E-4F61-92EC-0DCDED85147D wds:Q37587722-75AA6D8D-8DAC-4D5B-BEFF-8D982607044C wds:Q37587722-85345BD2-FD34-43AC-BE3E-7F9950BB1D71 wds:Q37587722-8EFC2F82-DC8F-40B4-8841-AB5E271ECE64 wds:Q37587722-97D8C8F0-E7AD-430E-9D29-462E6D07C333 wds:Q37587722-A8A12467-9213-47E9-87F7-57AFCD94C6F6 wds:Q37587722-AD76D46F-C113-4B76-9C2F-6C246B6B1EBE wds:Q37587722-B857891B-769E-4D71-888C-46B69FE49C6A wds:Q37587722-BC11467C-2E7B-4F49-82CF-8E3B079250E3 wds:Q37587722-BD619B5D-E9A7-48F0-B9E1-02A6E623DC8C wds:Q37587722-C4E746DA-B1A1-40B7-B02D-842940582003 wds:Q37587722-C54F7AC7-CB48-45F7-82FF-7A698C3A3E8C wds:Q37587722-C64F5B8E-82FF-4E11-B6F1-CED859E5F43C wds:Q37587722-D7E868DC-50D4-4F7C-9A57-EAF57AE74B83 wds:Q37587722-DF15F644-20C0-4303-863E-EDAF9F035889 wds:Q37587722-E299C01B-A01B-4326-8F09-0C7D1A44CC7A wds:Q37587722-E6883B73-8C32-4D50-8E46-9D1FAD069440 wds:Q37587722-F01EC93F-6FCF-467D-8D6B-9446C3E18288 wds:Q37587722-F3C5B28F-14E2-4C0D-9118-B36CC53B4E5F
cites work	Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Mucopolysaccharidosis I: management and treatment guidelines Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Elimination of antibodies to recombinant enzyme in Pompe's disease. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I The natural history of MPS I: global perspectives from the MPS I Registry Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies
author name string	wds:Q37587722-131CEB12-1452-4C0B-8597-A7030DE8FEE2 wds:Q37587722-156DCC1B-FB1D-4B70-8A7B-184832FB46B7 wds:Q37587722-37B12EDF-D90B-4CE3-AD1F-F9275215DECC wds:Q37587722-38EBA868-C56B-4263-AAFA-91701F39C1EA wds:Q37587722-67F5B5FB-BD99-4105-9E42-050574845E76 wds:Q37587722-8FE83707-09D2-45C3-B6C3-6FB47A60AA86 wds:Q37587722-FB78E0B3-E1D3-4C53-9155-2345E113816C
author name string	Yong Xue Susan Richards Gerald F Cox Clarissa Gutierrez Carvalho Alla N Semyachkina Maria-Veronica Muñoz-Rojas Taiane Alves Vieira
rdfs:label	Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (en) Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (nl) Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (ast)
skos:prefLabel	Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (en) Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (nl) Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (ast)
name	Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (en) Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (nl) Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. (ast)
author	wds:Q37587722-03D118CB-4687-4DDB-B163-89ADC8E41848 wds:Q37587722-C8868EFF-D2B6-4291-ADD4-8D6DABADBEDD
author	Roberto Giugliani

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software